A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.

Autor: Schlechter, Benjamin L., Olson, Daniel, Saibil, Samuel, George, Mridula Annette, Gruber, Kelly, Bouvier, Riemke, Pieke, Brooke, Geisburger, Jill, Moss, Kara M., Ternus, Nathan, Adib, Deyaa R, Dumbrava, Ecaterina Elena
Zdroj: Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, pTPS816-TPS816, 1p
Databáze: Supplemental Index